Real-world treatment patterns and survival in extensive stage small-cell lung cancer in Japan
Anti-PD-L1 therapies have become part of first-line standard of care but survival in treated Japanese ES-SCLC patients remains poor, highlighting the unmet medical need in the post anti-PD-L1 era.
Authors
- Xerxes Pundole (ORCID: https://orcid.org/0000-0002-3324-7398)
- Akhila Balasubramanian (ORCID: https://orcid.org/0009-0000-1256-2826)
- J.W. Shaw (ORCID: https://orcid.org/0000-0001-8379-8473)
- Hidehito Horinouchi (ORCID: https://orcid.org/0000-0001-9090-801X)
- Chia‐Hsien Chang (ORCID: https://orcid.org/0000-0002-6988-7944)
- Olga Archangelidi
Institutions
- Amgen (United States) (US)
- National Cancer Center (US)
- MSD K.K. (Japan) (JP)
- Amgen (United Kingdom) (GB)
- Brunel University of London (GB)
Publication Details
- Journal
- Japanese Journal of Clinical Oncology
- Published
- 2024-12-20
- DOI
- https://doi.org/10.1093/jjco/hyae175
- Citations
- 2
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.57
Funders
- Amgen